Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

BACKGROUND: Phase II trials found that tegafur–uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. Our Phase II randomized trial aimed to evaluate efficacy and tolerability of sorafen...

Descripción completa

Detalles Bibliográficos
Autores principales: Azim, Hamdy A, Omar, Ashraf, Atef, Hesham, Zawahry, Heba, Shaker, Mohamed K, Abdelmaksoud, AH Kamel, EzzElarab, Mohamed, Abdel-Rahman, Omar, Ismail, Mohamed, Kassem, Loay, Waked, Imam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250115/
https://www.ncbi.nlm.nih.gov/pubmed/30510922
http://dx.doi.org/10.2147/JHC.S169285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250115/
https://www.ncbi.nlm.nih.gov/pubmed/30510922
http://dx.doi.org/10.2147/JHC.S169285

Ejemplares similares